US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Provident

16.35

-0.2900-1.74%

Volume:109.71K

Turnover:1.79M

Market Cap:2.14B

PE:13.76

High:16.40

Open:16.39

Low:16.13

Close:16.64

Loading ...

Overview Company News Filings

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Impact raising up to $5.2m to develop Lake Hope HPA, exploration at Arkun and Broken Hill

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...

US Exchange: 3 Stocks That May Be Trading Below Estimated Value

Simply Wall St.

3 Value Stocks Estimated To Be Trading At Discounts Of Up To 47.3%

Simply Wall St.

3 Stocks That May Be Trading At An Estimated Discount Of Up To 33.1%

Simply Wall St.

Peninsula Family Service, A Leading Nonprofit Organization Dedicated to Strengthening Communities Across the Peninsula, Announces Year-long Celebration of its 75th Anniversary

Verra Mobility And Two Other US Stocks Estimated To Be Trading Below Intrinsic Value

Simply Wall St.

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

INAB: Continued Survival in INB-100 Trial

Zacks Small Cap Research

3 Stocks On US Exchange Estimated To Be Undervalued By Up To 36.2%

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PFS/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PFS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident","latestPrice":16.35,"timestamp":1746030344872,"preClose":16.64,"halted":0,"volume":109705,"delay":0,"floatShares":126167377,"shares":130663184,"eps":1.188092,"marketStatus":"Trading","change":-0.29,"latestTime":"04-30 12:25:48 EDT","open":16.39,"high":16.4,"low":16.125,"amount":1785350.2502050002,"amplitude":0.016526,"askPrice":16.34,"askSize":10,"bidPrice":16.32,"bidSize":35,"shortable":3,"etf":0,"ttmEps":1.188092,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1042693200000,"exchange":"NYSE","adjPreClose":16.64,"dividendRate":0.058716,"preHourTrading":{"tag":"盘前","latestPrice":16.55,"preClose":16.64,"latestTime":"04:15 EDT","volume":1,"amount":16.55,"timestamp":1746000914544},"postHourTrading":{"tag":"盘后","latestPrice":16.64,"preClose":16.64,"latestTime":"16:20 EDT","volume":42938,"amount":714488.32,"timestamp":1745958000438},"volumeRatio":0.296631,"impliedVol":0.0617,"impliedVolPercentile":0.092},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","floatShares":126167377,"roa":"0.77%","roe":"6.77%","lyrEps":1.053397,"volumeRatio":0.296631,"shares":130663184,"dividePrice":0.96,"high":16.4,"amplitude":0.016526,"preClose":16.64,"low":16.125,"week52Low":13.07,"pbRate":"0.80","psRate":"3.05","week52High":22.24,"institutionHeld":0.6698,"latestPrice":16.35,"committee":0.555556,"eps":1.188092,"divideRate":0.058716,"volume":109705,"delay":0,"ttmEps":1.188092,"open":16.39,"prevYearClose":18.87,"prevWeekClose":16.54,"prevMonthClose":17.17,"prevQuarterClose":17.17,"fiveDayClose":16.37,"twentyDayClose":17.19,"sixtyDayClose":18.23},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PFS\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516680252","title":"Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516680252","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516680252?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:05","pubTimestamp":1741003500,"startTime":"0","endTime":"0","summary":"Initial clinical readout from Phase 1 RP-3467  POLAR trial expected in Q3 2025. Initial clinical readout from Phase 1 RP-1664  LIONS trial expected in Q4 2025. $152.8 million in cash and cash equivalents and marketable securities provides runway to late-2027. CAMBRIDGE, Mass. & MONTREAL, March 03, 2025----Repare Therapeutics Inc.  , a clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2024.\"Our recently implemented re-structuring and the re-prioritization of our clinical portfolio meaningfully extends our cash runway into late 2027. We are now focused on three ongoing Phase 1 clinical trials with readouts expected in 2025: the LIONS trial evaluating our RP-1664 PLK4 inhibitor; the POLAR trial evaluating our RP-3467 Polθ ATPase inhibitor; and our ongoing MYTHIC trial evaluating lunresertib in combination with Debiopharm's WEE1 inhibitor, Debio 0123,\" said Lloyd M. Segal, President and Chief Executive Office","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/repare-therapeutics-provides-business-clinical-120500204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4195","EC","BK4007","BK4139","PROC","PFS","RPTX","LENZ","BK4201","BK4211"],"gpt_icon":0},{"id":"2514324925","title":"Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2514324925","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514324925?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:14","pubTimestamp":1740748440,"startTime":"0","endTime":"0","summary":"The positive opinion is based on results from the Phase 3 BRUIN CLL-321 trial, recently presented at the 2024 American Society of Hematology Annual Meeting. BRUIN CLL-321 is the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor. The positive opinion is supported by data from the BRUIN CLL-321 clinical trial, the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor. The study's primary endpoint of progression-free survival  was met at the prespecified time of final analysis , based on independent review committee  assessment, demonstrating pirtobrutinib was superior to investigator's choice of idelalisib plus rituximab  or bendamustine plus rituximab , both global standards of care.1 At an updated analysis , pirtobrutinib reduced therisk of disease progressionor death by 46% compared to IdelaR or BR, consistent with the primary analysis.PFS results were cons","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-recommended-chmp-131400700.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-recommended-chmp-131400700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237443465.HKD","LU1069344957.HKD","ORR","ASH","LU2237443622.USD","LU2237443382.USD","BK4226","LU0203201768.USD","LU0238689110.USD","BNTX","PRO","LU2461242641.AUD","LLY","LU1720051108.HKD","LU0640476718.USD","LU1974910355.USD","LU2602419157.SGD","LU0203202063.USD","BK4588","BK4109","LU1023059063.AUD","OS","LU2361045086.USD","LU0390134368.USD","LU0471298777.SGD","LU2063271972.USD","BK4516","BK4585","BK4599","LU2491050071.SGD","LU0882574139.USD","IE0009355771.USD","BK4533","BK4094","LU2237443978.SGD","LU1814569148.SGD","FL","CHMP","IE0002141913.USD","PFS","IE00BK4W5L77.USD","LU1267930730.SGD","LU1061106388.HKD","LU2211815571.USD","IE00BJT1NW94.SGD","LU2265009873.SGD","SG9999015986.USD","BR","SG9999001176.USD","LU0354030511.USD"],"gpt_icon":1},{"id":"2514329672","title":"ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514329672","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514329672?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:00","pubTimestamp":1740747600,"startTime":"0","endTime":"0","summary":"Recommendation based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year. TOKYO & MUNICH, February 28, 2025----Daiichi Sankyo  and AstraZeneca’s  ENHERTU  has been recommended for approval in the European Union  as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor  positive, HER2 low  or HER2 ultralow  breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate  discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.In the DESTINY-Breast06 trial, ENHERTU demonstrated a 38% reduction in the risk of disease progression or death versus chemotherapy in patients with chemotherapy-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-recommended-approval-eu-chmp-130000849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4203","BK4225","BK4195","BK4087","BK4080","ORR","BK4007","BK4156","PBD","BK4211","BK4231","DSNKY","ADC","DSKYF","CHMP","PFS","HR"],"gpt_icon":0},{"id":"2514994398","title":"Impact raising up to $5.2m to develop Lake Hope HPA, exploration at Arkun and Broken Hill","url":"https://stock-news.laohu8.com/highlight/detail?id=2514994398","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514994398?lang=en_us&edition=fundamental","pubTime":"2025-02-28 11:36","pubTimestamp":1740713804,"startTime":"0","endTime":"0","summary":"Impact Minerals raising up to $5.2m through a two-for-seven rights issue priced at 0.6c per share . Proceeds will fund the development of the Lake Hope HPA project and exploration at Arkun and Broken Hill. Raising expected to position company for next stage of growth","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-IPT-new-1200-640x359.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-IPT-new-1200-640x359.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/resources/impact-raising-up-to-5-2m-to-develop-lake-hope-hpa-exploration-at-arkun-and-broken-hill/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4195","BK4211","HOPE","PFS"],"gpt_icon":0},{"id":"2514596802","title":"IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2514596802","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514596802?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:05","pubTimestamp":1740661500,"startTime":"0","endTime":"0","summary":"IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in Q1 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3033835/0/en/IMUNON-Reports-2024-Financial-Results-and-Provides-Business-Update-Highlighting-Significant-Progress-Towards-the-Initiation-of-a-Pivotal-Phase-3-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4097","BK4203","IE00B1BXHZ80.USD","OS","BK4139","SITC","CMC","IE00BZ1G4Q59.USD","BK4225","LU0971096721.USD","PFS","BK4211","BK4080","LU0882574139.USD","LU1363072403.SGD","IMNN","LU0170899867.USD","IE00BHPRN162.USD","IE00BKVL7J92.USD","LU0149725797.USD","LU2065732104.USD","LU0267386448.USD","PRGS","HR","BK4195","BK4231"],"gpt_icon":0},{"id":"2514895520","title":"Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications","url":"https://stock-news.laohu8.com/highlight/detail?id=2514895520","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514895520?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:48","pubTimestamp":1740606480,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., February 26, 2025----Agenus Inc. , a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy.Agenus is advancing a robust clinical pipeline targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, tumor microenvironment conditioning agents and cell therapies . Our most advanced antibody candidates, botensilimab  an Fc-enhanced CTLA-4 blocking antibody, and balstilimab , a novel, PD-1 inhibitor, are central to our efforts.BOT is currently being investigated as a monotherapy and in combination with widely used standard of care anti-PD-1, chemotherapy, and allogeneic cell therapy across multiple indications:. Dr. O’Day continues, \"By leveraging our deep expertise in immune activation, we are unlocking responses in tumors previously resistant to immunotherapy. The results are even more promising as we move from treatment refractory me","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agenus-reports-impact-key-immuno-214800977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","LU0456854461.SGD","PFS","BK4211","LU0266512127.USD","R","CRC","BK4097","BK4232","BK4113","BK4139","BK4213","BK4022","AGEN","BAL","ORR","BK4195","MSS"],"gpt_icon":0},{"id":"2514898618","title":"Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514898618","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514898618?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:05","pubTimestamp":1740603900,"startTime":"0","endTime":"0","summary":"Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer. Continued progression of other front-line breast cancer regimens, including initiation of atirmociclib triplet, and planning for development of future oral endocrine therapy combinations underway. Approximately $780 million in cash, cash equivalents and investments at end of Q4 2024, which will be prioritized to fully fund the execution of the ReDiscover-2 Phase 3 trial. CAMBRIDGE, Mass., Feb. 26, 2025  -- Relay Therapeutics, Inc. , a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported fourth quarter and full year 2024 financial results and corporate highlights.Relay Tx has conducted an end of Phase 2 meeting with the Food and Drug Administration  and announces the Phase 3 trial design, dose, and pla","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relay-therapeutics-reports-fourth-quarter-210500946.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RLAY","BK4563","BK4211","ORR","PFS","BK4139","BK4195"],"gpt_icon":0},{"id":"2514867732","title":"Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2514867732","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514867732?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:02","pubTimestamp":1740603720,"startTime":"0","endTime":"0","summary":"Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026. Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancer. Company anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025. Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time. REDWOOD CITY, Calif., Feb. 26, 2025  -- Revolution Medicines, Inc. , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter and full year ended December 31, 2024, and provided an update on corporate progress.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revolution-medicines-reports-fourth-quarter-210200565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","LU0124384867.USD","LU1720051108.HKD","RVMD","LU1854103824.USD","LU1720051017.SGD","BK4585","IE00B7SZLL34.SGD","BK4139","IE00BZ199S13.USD","LU0058720904.USD","BK4166","LU1059921491.USD","LU0868494617.USD","BK4211","LU0724618433.USD","LU1861214812.USD","MDCO","IE00BD6J9T35.USD","LU1861215975.USD","LU2357305700.SGD","CI","LU1861220033.SGD","LU2065732104.USD","BK4092","LU1861219969.SGD","LU2298322129.HKD","ON","PRGS","QD","RVMDW","BK4605","LU0289739699.SGD","LU1548497426.USD","LU1978683503.SGD","LU0348723411.USD","BK4195","BK4512","PFS","LU1854104046.USD","BK4563","NE","BK4503","IE00B19Z3B42.SGD","BK4097","IE0002270589.USD","IE00B19Z3581.USD","BK4588","LU2360107325.USD","OS"],"gpt_icon":0},{"id":"2514983992","title":"Immunocore reports fourth quarter and full year 2024 financial results and provides a business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514983992","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514983992?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"KIMMTRAK  Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025. Executing on KIMMTRAK lifecycle management with two Phase 3 trials  in additional melanoma indications. Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C . First patient dosed in Phase 1/2 trial of IMC-R117C  in colorectal and other gastrointestinal cancers. CTA/IND on track for IMC-S118AI  in 2H 2025 and for IMC-U120AI, our first non-HLA-restricted candidate initially for atopic dermatitis, in 2026. Cash, cash equivalents and marketable securities of $820.4 million as of December 31, 2024. “In 2024, we continued to grow KIMMTRAK sales, execute on our KIMMTRAK lifecycle management program, advance our deep clinical pipeline, and expand into autoimmune diseases, supported by a strong cash position and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunocore-reports-fourth-quarter-full-120000489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756168.USD","BK4195","BK4533","ALT","IE0031619046.USD","LU1093756325.SGD","BK4007","BK4567","BK4121","CRS","IE00BFXG0V08.USD","LU2413666426.HKD","ORR","BK4505","BK4585","BK4588","BK4006","BK4139","BK4548","LU2065731478.USD","BK4207","LU0347712357.USD","PFS","OS","BK4147","CTA","BK4211","LU1721428933.USD","BK4599","BK4097","LU2413666699.HKD","MTD","ATOM","LU1878469433.USD","IE00BYQQ9H92.USD","IMCR","PROC","IE00B66KJ199.SGD","IE00B7SZL793.SGD","CM","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2514831987","title":"Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2514831987","media":"Business Wire","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514831987?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"First and only next-generation oral SERD and complete ER antagonist to demonstrate 1st-line benefit in combination with widely approved CDK4/6 inhibitors. The key secondary endpoints of time to second disease progression  and overall survival  were immature at the time of this interim analysis. However, the camizestrant combination demonstrated a trend toward improvement in PFS2. The trial will continue as planned to further assess key secondary endpoints.Susan Galbraith, Executive Vice President, Oncology Hematology R&D, AstraZeneca, said: \"These impressive results demonstrate the versatility of camizestrant in combination with all the widely approved CDK4/6 inhibitors to provide a well-tolerated new potential treatment option in the first-line setting for the one in three patients with HR-positive, HER2-negative advanced breast cancer whose tumors develop ESR1 mutations during","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/camizestrant-demonstrated-highly-statistically-significant-120000062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","LU2456880835.USD","LU0109394709.USD","BK4225","BK4585","PFS","BK4195","LU2236285917.USD","LU0320765992.SGD","BK4203","BK4588","III","LU0889565916.HKD","LU2462157665.USD","HR","BK4211","AZN","OS","BK4568","BK4007","BK4134","LU2417539215.USD","LU1829250122.USD"],"gpt_icon":0},{"id":"2514044305","title":"Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514044305","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514044305?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:05","pubTimestamp":1740517500,"startTime":"0","endTime":"0","summary":"New data from the Phase 1/1b ARC-20 study showed that casdatifan improved upon the rate of primary progression, overall response rate  and progression-free survival  relative to published data from studies with HIF-2a inhibitors to date. Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan in combination with cabozantinib versus cabozantinib in immuno-oncology -experienced patients with clear cell renal cell carcinoma  is expected in the first half of 2025; initial data from the cohort of ARC-20 evaluating casdatifan plus cabozantinib are expected to be presented in mid-2025. Arcus completed a $150 million financing and continues to be well positioned to advance its pipeline with $992 million in cash, cash equivalents and marketable securities as of December 31, 2024 . HAYWARD, Calif., February 25, 2025----Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcus-biosciences-reports-fourth-quarter-210500045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RCUS","BK4211","BK4195","ORR","BK4139","PFS"],"gpt_icon":0},{"id":"2513051728","title":"U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...","url":"https://stock-news.laohu8.com/highlight/detail?id=2513051728","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513051728?lang=en_us&edition=fundamental","pubTime":"2025-02-24 19:59","pubTimestamp":1740398340,"startTime":"0","endTime":"0","summary":"Application based on analyses from the Phase 3 CheckMate -8HW clinical trial, in which Opdivo plus Yervoy demonstrated superior progression-free survival compared to Opdivo monotherapy and investigator’s choice of chemotherapy. The U.S. Food and Drug Administration assigned a target action date of June 23, 2025. U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo Plus Yervoy for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer. Opdivo plus Yervoy received approval from the U.S. FDA in July 2018 for the treatment of adult and pediatric patients 12 years and older with MSI-H or dMMR mCRC that have progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan. Opdivo plus Yervoy was also approved in December 2024 in the European Union for the first-line treatment of adult patients with MSI-H or dMMR unresectable or mCRC and in October","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-food-drug-administration-accepts-115900916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4008","IE00BFTCPJ56.SGD","LU1074936037.SGD","BK4559","LU1291159041.SGD","LU1261432733.SGD","LU1323610961.USD","LU2360032135.SGD","LU1868836591.USD","BK4585","BK4534","IE0002141913.USD","BK4124","LU1585245621.USD","LU1670710588.SGD","MYE","BK4581","LU0868494617.USD","BMY","BK4211","LU1093756168.USD","LU1868837136.USD","VOD","LU0882574055.USD","CRT","LU1032466523.USD","LU2125154778.USD","IE0009355771.USD","LU1868836757.USD","LU2242646821.SGD","LU2242652126.USD","BK4532","RCC","BK4144","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0061475181.USD","LU2133065610.SGD","LU0266512127.USD","TEN","BK4195","PFS","LU0096364046.USD","BK4126","LU0985481810.HKD","HSCT","HCC","CRC","LU1670711123.USD","ALK"],"gpt_icon":0},{"id":"2512041214","title":"US Exchange: 3 Stocks That May Be Trading Below Estimated Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2512041214","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512041214?lang=en_us&edition=fundamental","pubTime":"2025-02-20 18:02","pubTimestamp":1740045745,"startTime":"0","endTime":"0","summary":"As the S&P 500 reaches new record highs, investors are keeping a close eye on market dynamics and potential opportunities within the U.S. stock exchanges. In this environment, identifying stocks that may be trading below their estimated value can offer intriguing prospects for those looking to capitalize on potential market inefficiencies.Top 5 Undervalued Stocks Based On Cash Flows In The United States. CoStar Group is trading at US$79.21, below its estimated fair value of US$91.29, suggesting potential undervaluation based on cash flows. Revenue growth is expected to outpace the broader market, with a forecast of 11.1% annually. Despite a decline in profit margins from 15.3% to 5.1%, earnings are projected to grow significantly at 34.9% per year, highlighting robust future prospects amidst recent strategic client partnerships and a substantial share repurchase program worth US$500 million.Overview: Mobileye Global Inc. develops and deploys advanced driver assistance systems and auton","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/us-exchange-3-stocks-may-100225842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2298321311.HKD","LU1920062954.HKD","BK4124","LU0654597011.USD","LU0012050646.USD","LU1119994140.HKD","LU1169590202.USD","LU0471298777.SGD","LU0471298694.HKD","LU1169589451.USD","IE00B64QTZ34.USD","LU0106261612.USD","PANW","IE0004445239.USD","LU2242652126.USD","LU0672654240.SGD","LU1863844749.USD","LU2092937221.SGD","LU0205193047.USD","LU0320765059.SGD","BK4211","LU2360108059.USD","LU0997586606.USD","BK4198","HAE","SW","LU0109391861.USD","LU1989763427.SGD","LU2210149790.SGD","LU1267930730.SGD","LU1803068623.USD","LU2401740654.USD","BK4195","CTRE","BK4203","LU0708995401.HKD","BK4079","BK4123","LU0612318385.USD","LU2242646821.SGD","BK4136","LU2210150020.SGD","LU0997587240.USD","LU1863844665.USD","LU2095319765.USD","LU2360106947.USD","BK4585","MBLY","CSGP","PFS","LU2041044095.USD"],"gpt_icon":1},{"id":"2512460006","title":"3 Value Stocks Estimated To Be Trading At Discounts Of Up To 47.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512460006","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512460006?lang=en_us&edition=fundamental","pubTime":"2025-02-20 13:02","pubTimestamp":1740027751,"startTime":"0","endTime":"0","summary":"As global markets navigate higher-than-expected inflation data and fluctuating interest rate expectations, U.S. stock indexes are climbing toward record highs, with growth stocks outperforming value shares. In this environment, identifying undervalued stocks can offer investors potential opportunities to capitalize on market inefficiencies, particularly when these stocks are trading at significant discounts relative to their intrinsic value.Overview: Ratchthani Leasing Public Company Limited, along with its subsidiary, offers hire-purchase and leasing services in Thailand and has a market cap of THB9.84 billion.Ratchthani Leasing is trading at 47.3% below its fair value estimate of THB3, highlighting its undervaluation based on cash flows. Despite a volatile share price recently, earnings are expected to grow significantly at 26% annually, outpacing the Thai market's growth rate. However, the company faces challenges with high debt levels and a recent decline in revenue and net incom","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-value-stocks-estimated-trading-050231590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1430597077.USD","BK4211","LU1863844749.USD","LU2242652126.USD","LU0471298694.HKD","BK4136","LU2401740654.USD","LU1920063259.USD","LU0612318385.USD","PFS","LU2360108059.USD","LU1803068623.USD","LU1989763690.USD","LU2360106947.USD","LU0048578792.EUR","BK4195","LU1989763427.SGD","LU1892829315.USD","SW","LU0997587240.USD","LU0385154629.USD","LU2380233275.USD","LU0654597011.USD","PSSEF","LU2242646821.SGD","LU0471298777.SGD","LU2041044095.USD","LU0997586606.USD","LU1863844665.USD","LU1920062954.HKD","LU2298321311.HKD","BK4152","LU2242646235.USD","LU0612318971.USD","LU0550127509.SGD","LU2092937221.SGD"],"gpt_icon":0},{"id":"2512976462","title":"3 Stocks That May Be Trading At An Estimated Discount Of Up To 33.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512976462","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512976462?lang=en_us&edition=fundamental","pubTime":"2025-02-20 12:02","pubTimestamp":1740024148,"startTime":"0","endTime":"0","summary":"As global markets navigate a landscape marked by climbing U.S. stock indexes and heightened inflation expectations, investors are keenly observing opportunities for value amidst the volatility. In this environment, identifying stocks that may be trading at an estimated discount can offer potential advantages, as these investments might provide room for growth when market conditions stabilize.Metso Oyj appears undervalued based on discounted cash flow analysis, trading at 10.88 compared to an estimated fair value of 12.88. Although not significantly undervalued, its earnings are expected to grow faster than the Finnish market at 12% annually. Despite high debt levels and a dividend yield of 3.49% not fully covered by free cash flows, Metso's strategic equipment installations in projects like Sangdong could enhance long-term operational capabilities and revenue growth prospects.Operations: The company's revenue is primarily derived from its Civil Aviation segment, which accounts for CA$2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-stocks-may-trading-estimated-040228669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU0550127509.SGD","LU2092937221.SGD","CAE","LU0048578792.EUR","LU2401740654.USD","LU2242652126.USD","LU0612318385.USD","LU2242646821.SGD","SSRM","LU2041044095.USD","OUKPY","LU0612318971.USD","LU1989763427.SGD","LU1803068623.USD","LU1863844749.USD","LU0471298694.HKD","LU1863844665.USD","SSR.AU","LU1920063259.USD","LU2298321311.HKD","SW","BK4136","BK7104","LU1989763690.USD","LU2360106947.USD","LU2360108059.USD","PFS","BK4195","BK7506","LU0471298777.SGD","LU0997586606.USD","LU1920062954.HKD","BK4211","OUKPF","LU2242646235.USD","LU0654597011.USD","LU1892829315.USD","LU2380233275.USD","LU1430597077.USD","LU0997587240.USD","LU0385154629.USD"],"gpt_icon":0},{"id":"2512454869","title":"Peninsula Family Service, A Leading Nonprofit Organization Dedicated to Strengthening Communities Across the Peninsula, Announces Year-long Celebration of its 75th Anniversary","url":"https://stock-news.laohu8.com/highlight/detail?id=2512454869","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512454869?lang=en_us&edition=fundamental","pubTime":"2025-02-20 08:27","pubTimestamp":1740011220,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Feb. 19, 2025 /PRNewswire/ --Peninsula Family Service , a leading nonprofit organization dedicated to empowering individuals and families across the Peninsula, is proud to announce a year-long celebration marking its 75th anniversary. Since 1950, PFS has been a trusted community partner, providing essential services that enable community members to lead healthy, stable lives.Over the past seven and a half decades, PFS has expanded to offer more than 45 programs and services, reaching over 10,000 neighbors annually in San Mateo and Santa Clara counties. These programs encompass early learning, financial empowerment, older adult support, and employment services, all designed to help individuals realize their full potential. As the organization marks this achievement, it remains committed to expanding access to resources that build stronger communities for the next 75 years and beyond.Peninsula Family Service  strengthens communities across San Mateo and Santa Clara cou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/peninsula-family-leading-nonprofit-organization-002700383.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/peninsula-family-leading-nonprofit-organization-002700383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","PFS","BK4195"],"gpt_icon":0},{"id":"2512488802","title":"Verra Mobility And Two Other US Stocks Estimated To Be Trading Below Intrinsic Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2512488802","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512488802?lang=en_us&edition=fundamental","pubTime":"2025-02-19 22:02","pubTimestamp":1739973756,"startTime":"0","endTime":"0","summary":"As the S&P 500 reaches new heights and major indices hover near record levels, investors are keenly observing market movements to identify potential opportunities. In this environment, identifying stocks trading below their intrinsic value can be a strategic move for those looking to capitalize on undervalued assets; Verra Mobility and two other U.S. stocks stand out as candidates potentially offering such value amidst these conditions.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Verra Mobility appears undervalued based on cash flows, trading at US$26.55 against a fair value estimate of US$48.97, suggesting a significant discount. Despite slower revenue growth projections of 6.5% annually compared to the broader market, its earnings are forecasted to grow significantly at 23.1% per year, outpacing the market average of 14.5%. Recent enhancements in its buyback plan by an additional US$100 million underscore management's confidence in its financial health and futu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verra-mobility-two-other-us-140236675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2242652126.USD","BK4225","BK4134","LU1892829315.USD","BK4203","LU2401740654.USD","IE0031619046.USD","LU1430597077.USD","CSTM","LU0997587240.USD","BK4195","LU0550127509.SGD","LU2092937221.SGD","LU2360106947.USD","FRPT","LU2360108059.USD","BK4153","LU0048578792.EUR","LU1920062954.HKD","SW","VRRM","IE00B66KJ199.SGD","PFS","KD","BK4211","LU1863844749.USD","IE00B7SZL793.SGD","LU2242646821.SGD","LU0471298694.HKD","LU1863844665.USD","LU1920063259.USD","LU0654597011.USD","LU2242646235.USD","LU2041044095.USD","BK4136","LU0385154629.USD","LU1989763690.USD","LU0997586606.USD","IE00B19Z4B17.USD","LU0612318385.USD","LU2298321311.HKD","LU1989763427.SGD","LU0612318971.USD","LU1803068623.USD","LU0471298777.SGD","CTRE","LU2380233275.USD"],"gpt_icon":0},{"id":"2512104071","title":"Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2512104071","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512104071?lang=en_us&edition=fundamental","pubTime":"2025-02-19 20:30","pubTimestamp":1739968200,"startTime":"0","endTime":"0","summary":"– Total Revenue of $145 Million and U.S. XPOVIO  Net Product Revenue of $113 Million for Full Year 2024 –。–Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Nave Myelofibrosis Anticipated in 2H 2025; Company on Track to Complete Enrollment in 1H 2025 –。–Company Announces Update to Phase 3 XPORT-EC-042 Trial of Selinexor as Maintenance Therapy in Advanced or Recurrent TP53 Wild-Type Endometrial Cancer. Following Dialogue with the FDA Regarding the Evolving Treatment Landscape, Trial to Focus Enrollment on Patients with Either pMMR Tumors or Patients with dMMR Tumors that are Medically Ineligible for Checkpoint Inhibitors. Increasing Sample Size to 276; Top-Line Data Now Expected in Mid-2026 –。– Company Provides Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million, Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million –","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/karyopharm-reports-fourth-quarter-full-123000326.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/karyopharm-reports-fourth-quarter-full-123000326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","BK4161","OS","PRGS","LU0054578231.USD","EC","ITT","PFS","LU2065732104.USD","BK4195","LU0053671581.USD","BK4139","BK4211","KPTI","BK4201"],"gpt_icon":0},{"id":"2512484426","title":"INAB: Continued Survival in INB-100 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2512484426","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512484426?lang=en_us&edition=fundamental","pubTime":"2025-02-19 19:11","pubTimestamp":1739963460,"startTime":"0","endTime":"0","summary":"IN8bio, Inc  updates survival data for its INB-100 trial in a February 11thpress release in preparation for presentation of data at the Transplantation & Cellular Therapy  Meetings in Hawaii last week. Data for patients enrolled in the trial were updated from early August 2024 to January 17th, 2025. All of the acute myeloid leukemia  patients across both original and expansion cohorts remain in complete remission , with a median follow-up of 20.1 months. All of the AML patients achieved one year of progression free survival  and overall survival . Since our last update, IN8bio has participated in multiple investor and scientific conferences, including Biotech Showcase, Noble’s Emerging Growth Conference, the American Society of Hematology Annual Meeting and the TCT meetings.The results are remarkable as real-world survival rates for AML patients following hematopoietic stem cell transplantation  are lower. For example, the Center for International Blood and Marrow Transplant Research  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inab-continued-survival-inb-100-111100490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INAB","BK4161","CRS","HSCT","PFS","INB","LU2065731478.USD","BK4539","BK4195","IE00B7SZL793.SGD","BK4139","CR","BK4211","BK4006","IE00B19Z4B17.USD","OS","BK4097","IE00B66KJ199.SGD","IE0031619046.USD"],"gpt_icon":0},{"id":"2512172306","title":"3 Stocks On US Exchange Estimated To Be Undervalued By Up To 36.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512172306","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512172306?lang=en_us&edition=fundamental","pubTime":"2025-02-19 18:02","pubTimestamp":1739959339,"startTime":"0","endTime":"0","summary":"As the U.S. stock market continues to reach new heights, with the S&P 500 recently setting a record high, investors are increasingly on the lookout for opportunities that may be undervalued amidst this rally. In such an environment, identifying stocks that are trading below their intrinsic value can offer potential growth opportunities, especially when broader market indices are performing strongly.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Overview: DexCom, Inc. is a medical device company that specializes in the design, development, and commercialization of continuous glucose monitoring systems globally, with a market cap of approximately $34.80 billion.Overview: GeneDx Holdings Corp. is a genomics company that offers personalized health insights to aid in diagnosis, treatment, and drug discovery, with a market cap of approximately $2.10 billion.Operations: GeneDx Holdings Corp. generates revenue by providing genomics-based personalized health insights that s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-stocks-us-exchange-estimated-100219150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1548497426.USD","LU1920062954.HKD","LU2298321311.HKD","BK4545","BK4153","LU2211815571.USD","LU0471298694.HKD","DXCM","CSTM","KD","LU0550127509.SGD","IE00B66KJ199.SGD","LU2242652126.USD","LU1863844749.USD","BK4548","ALB","BK4211","LU1974910355.USD","LU0997586606.USD","LU1989763690.USD","LU0354030511.USD","PFS","SW","BK4082","LU1989763427.SGD","LU1861214812.USD","LU1803068623.USD","LU2401740654.USD","BK4195","BK4551","CTRE","LU0385154629.USD","LU1917777945.USD","LU2249611893.SGD","LU1920063259.USD","IE00B7SZL793.SGD","LU1244550221.USD","WGS","BK4136","LU2360106947.USD","LU0997587240.USD","LU1720051108.HKD","LU1863844665.USD","LU1892829315.USD","BK4585","LU1923622614.USD","LU2106854487.HKD","LU2357305700.SGD","WGSWW","BK4134","BK4109","LU0354030438.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PFS\",params:#limit:5,,,undefined,":[{"date":"2025-05-16","symbol":"PFS","amount":0.24,"announcedDate":"2025-04-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-16","defaultRemindTime":1747402200000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-30","payableDate":"2025-05-16","currency":"USD","dateTimestamp":1747368000000,"payDate":"2025-05-30"},{"date":"2025-04-24","symbol":"PFS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":0.47,"defaultRemindTime":1745524800000,"name":null,"time":"Post Market","dateTimestamp":1745467200000,"actualEps":null},{"date":"2025-02-14","symbol":"PFS","amount":0.24,"announcedDate":"2025-01-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-14","defaultRemindTime":1739543400000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-28","payableDate":"2025-02-14","currency":"USD","dateTimestamp":1739509200000,"payDate":"2025-02-28"},{"market":"US","date":"2025-01-28","symbol":"PFS","fiscalQuarterEnding":"2024/12","expectedEps":0.5,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738040400000,"reportTimeType":"post","actualEps":0.37},{"date":"2024-11-15","symbol":"PFS","amount":0.24,"announcedDate":"2024-10-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-15","defaultRemindTime":1731681000000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-29","payableDate":"2024-11-15","currency":"USD","dateTimestamp":1731646800000,"payDate":"2024-11-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PFS\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-13","recordDate":"2015-05-15","paymentDate":"2015-05-29","value":0.16,"currency":"USD"},{"executeDate":"2015-08-12","recordDate":"2015-08-14","paymentDate":"2015-08-28","value":0.16,"currency":"USD"},{"executeDate":"2015-11-10","recordDate":"2015-11-13","paymentDate":"2015-11-27","value":0.17,"currency":"USD"},{"executeDate":"2016-02-10","recordDate":"2016-02-12","paymentDate":"2016-02-26","value":0.17,"currency":"USD"},{"executeDate":"2016-05-11","recordDate":"2016-05-13","paymentDate":"2016-05-31","value":0.18,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PFS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.8333,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1734148800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PFS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PFS","date":"2025-04-29","current":14.646015,"percent":0.743089,"low":6.410614,"twenty":8.698894,"median":10.357421,"eighty":16.512412,"high":33.980228,"avg":12.892668,"sd":6.39844,"marketCap":2159862431},"quantilePoints":[{"date":"2020-05-01","current":9.095426,"twenty":14.024503,"median":17.544322,"eighty":19.049774,"marketCap":879291222},{"date":"2020-05-08","current":8.942283,"twenty":13.850794,"median":17.544322,"eighty":19.049774,"marketCap":864486279},{"date":"2020-05-15","current":7.690497,"twenty":13.45386,"median":17.544322,"eighty":19.049774,"marketCap":743471074},{"date":"2020-05-22","current":8.31639,"twenty":13.355525,"median":17.544322,"eighty":19.049774,"marketCap":803978677},{"date":"2020-05-29","current":8.675946,"twenty":13.325105,"median":17.544322,"eighty":19.049774,"marketCap":838738363},{"date":"2020-06-05","current":10.060901,"twenty":13.301991,"median":17.544322,"eighty":19.049774,"marketCap":972627526},{"date":"2020-06-12","current":8.802456,"twenty":13.236148,"median":17.54157,"eighty":19.049774,"marketCap":850968623},{"date":"2020-06-19","current":8.702579,"twenty":13.220184,"median":17.524378,"eighty":19.049774,"marketCap":841313155},{"date":"2020-06-26","current":8.695921,"twenty":13.193521,"median":17.503783,"eighty":19.049774,"marketCap":840669457},{"date":"2020-07-02","current":9.022184,"twenty":13.181803,"median":17.497343,"eighty":19.049774,"marketCap":872210654},{"date":"2020-07-10","current":8.9556,"twenty":13.133798,"median":17.475453,"eighty":19.049774,"marketCap":865773675},{"date":"2020-07-17","current":9.375082,"twenty":13.113766,"median":17.448564,"eighty":19.049774,"marketCap":906326643},{"date":"2020-07-24","current":9.601469,"twenty":13.098537,"median":17.431245,"eighty":19.049774,"marketCap":928212371},{"date":"2020-07-31","current":10.146984,"twenty":13.0648,"median":17.422118,"eighty":19.049774,"marketCap":878647633},{"date":"2020-08-07","current":10.689643,"twenty":13.048711,"median":17.403942,"eighty":19.049774,"marketCap":925637580},{"date":"2020-08-14","current":10.527035,"twenty":13.031177,"median":17.388517,"eighty":19.049774,"marketCap":911556975},{"date":"2020-08-21","current":9.599052,"twenty":13.008395,"median":17.362339,"eighty":19.049774,"marketCap":831201106},{"date":"2020-08-28","current":9.947973,"twenty":12.988694,"median":17.334295,"eighty":19.049774,"marketCap":861414913},{"date":"2020-09-04","current":10.155841,"twenty":12.944965,"median":17.31872,"eighty":19.049774,"marketCap":879414627},{"date":"2020-09-11","current":9.509966,"twenty":12.926046,"median":17.247931,"eighty":19.049774,"marketCap":823486942},{"date":"2020-09-18","current":9.539661,"twenty":12.903594,"median":17.204455,"eighty":19.049774,"marketCap":826058330},{"date":"2020-09-25","current":8.916057,"twenty":12.85637,"median":17.165483,"eighty":19.049774,"marketCap":772059186},{"date":"2020-10-02","current":9.457999,"twenty":12.836682,"median":17.1464,"eighty":19.049774,"marketCap":818987014},{"date":"2020-10-09","current":9.777225,"twenty":12.825762,"median":17.106994,"eighty":19.030829,"marketCap":846629433},{"date":"2020-10-16","current":9.658443,"twenty":12.807943,"median":17.057235,"eighty":18.996004,"marketCap":836343881},{"date":"2020-10-23","current":10.222656,"twenty":12.774984,"median":17.027417,"eighty":18.941136,"marketCap":885200250},{"date":"2020-10-30","current":10.595048,"twenty":12.75677,"median":16.971439,"eighty":18.91343,"marketCap":872343311},{"date":"2020-11-06","current":10.696549,"twenty":12.723452,"median":16.947615,"eighty":18.891695,"marketCap":880700321},{"date":"2020-11-13","current":13.674488,"twenty":12.723452,"median":16.898923,"eighty":18.890505,"marketCap":1125888942},{"date":"2020-11-20","current":14.639195,"twenty":12.723452,"median":16.877422,"eighty":18.890505,"marketCap":1205318094},{"date":"2020-11-27","current":15.191794,"twenty":12.723452,"median":16.856678,"eighty":18.890505,"marketCap":1250816345},{"date":"2020-12-04","current":16.053474,"twenty":12.723452,"median":16.820466,"eighty":18.876273,"marketCap":1321762772},{"date":"2020-12-11","current":16.072206,"twenty":12.723452,"median":16.79439,"eighty":18.876273,"marketCap":1323305085},{"date":"2020-12-18","current":16.222063,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1335643594},{"date":"2020-12-24","current":16.718466,"twenty":12.723452,"median":16.730308,"eighty":18.876273,"marketCap":1376514905},{"date":"2020-12-31","current":16.821493,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1384997630},{"date":"2021-01-08","current":18.095281,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1489874956},{"date":"2021-01-15","current":17.992254,"twenty":12.723452,"median":16.744122,"eighty":18.876273,"marketCap":1481392232},{"date":"2021-01-22","current":18.142111,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1493730740},{"date":"2021-01-29","current":14.720538,"twenty":12.723452,"median":16.78893,"eighty":18.876273,"marketCap":1427170886},{"date":"2021-02-05","current":15.094115,"twenty":12.723452,"median":16.757917,"eighty":18.876273,"marketCap":1463389586},{"date":"2021-02-12","current":15.571023,"twenty":12.723452,"median":16.755695,"eighty":18.876273,"marketCap":1509626224},{"date":"2021-02-19","current":15.626662,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1515020498},{"date":"2021-02-26","current":16.079724,"twenty":12.723452,"median":16.714233,"eighty":18.876273,"marketCap":1558945304},{"date":"2021-03-05","current":17.794179,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1725163471},{"date":"2021-03-12","current":18.789768,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1821686827},{"date":"2021-03-19","current":18.215526,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1766013442},{"date":"2021-03-26","current":18.002063,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1745317972},{"date":"2021-04-01","current":17.749069,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1720790008},{"date":"2021-04-09","current":18.24715,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1769079438},{"date":"2021-04-16","current":18.405271,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1784409415},{"date":"2021-04-23","current":18.674076,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1810470378},{"date":"2021-04-30","current":14.042944,"twenty":12.721872,"median":16.669814,"eighty":18.884491,"marketCap":1833713567},{"date":"2021-05-07","current":15.049841,"twenty":12.721872,"median":16.625436,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-05-14","current":15.169001,"twenty":12.721872,"median":16.591954,"eighty":18.884491,"marketCap":1980752967},{"date":"2021-05-21","current":15.133253,"twenty":12.721872,"median":16.545238,"eighty":18.884491,"marketCap":1976085049},{"date":"2021-05-28","current":15.049841,"twenty":12.721872,"median":16.529666,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-06-04","current":15.043883,"twenty":12.721872,"median":16.506308,"eighty":18.884491,"marketCap":1964415256},{"date":"2021-06-11","current":14.722153,"twenty":12.721872,"median":16.44402,"eighty":18.884491,"marketCap":1922403999},{"date":"2021-06-18","current":13.679507,"twenty":12.721872,"median":16.40509,"eighty":18.884491,"marketCap":1786256407},{"date":"2021-06-25","current":14.227641,"twenty":12.721872,"median":16.3245,"eighty":18.884491,"marketCap":1857831141},{"date":"2021-07-02","current":13.500768,"twenty":12.721872,"median":16.302281,"eighty":18.884491,"marketCap":1762916819},{"date":"2021-07-09","current":13.244575,"twenty":12.721872,"median":16.261288,"eighty":18.884491,"marketCap":1729463411},{"date":"2021-07-16","current":12.976467,"twenty":12.721872,"median":16.250162,"eighty":18.884491,"marketCap":1694454030},{"date":"2021-07-23","current":12.55345,"twenty":12.69964,"median":16.222063,"eighty":18.884491,"marketCap":1639217007},{"date":"2021-07-30","current":10.433885,"twenty":12.684833,"median":16.184117,"eighty":18.884491,"marketCap":1680450278},{"date":"2021-08-06","current":10.849309,"twenty":12.675728,"median":16.148152,"eighty":18.884491,"marketCap":1747357095},{"date":"2021-08-13","current":10.552042,"twenty":12.660863,"median":16.109223,"eighty":18.884491,"marketCap":1699480276},{"date":"2021-08-20","current":10.381313,"twenty":12.614911,"median":16.079724,"eighty":18.884491,"marketCap":1671983067},{"date":"2021-08-27","current":10.571012,"twenty":12.560516,"median":16.051403,"eighty":18.884491,"marketCap":1702535521},{"date":"2021-09-03","current":10.362343,"twenty":12.528973,"median":16.012247,"eighty":18.884491,"marketCap":1668927821},{"date":"2021-09-10","current":10.43348,"twenty":12.478039,"median":15.976834,"eighty":18.884491,"marketCap":1680384992},{"date":"2021-09-17","current":10.542557,"twenty":12.463634,"median":15.915973,"eighty":18.884491,"marketCap":1697952653},{"date":"2021-09-24","current":10.841334,"twenty":12.367008,"median":15.852207,"eighty":18.884491,"marketCap":1746072768},{"date":"2021-10-01","current":11.315583,"twenty":12.317066,"median":15.827979,"eighty":18.884491,"marketCap":1822453904},{"date":"2021-10-08","current":11.718695,"twenty":12.271397,"median":15.788905,"eighty":18.884491,"marketCap":1887377870},{"date":"2021-10-15","current":11.713953,"twenty":12.250326,"median":15.716295,"eighty":18.884491,"marketCap":1886614059},{"date":"2021-10-22","current":11.808802,"twenty":12.188782,"median":15.680935,"eighty":18.884491,"marketCap":1901890286},{"date":"2021-10-29","current":11.169949,"twenty":12.144658,"median":15.649322,"eighty":18.884491,"marketCap":1912127768},{"date":"2021-11-05","current":11.584988,"twenty":12.022084,"median":15.636232,"eighty":18.884491,"marketCap":1983176134},{"date":"2021-11-12","current":11.413559,"twenty":11.87183,"median":15.555472,"eighty":18.877325,"marketCap":1953830070},{"date":"2021-11-19","current":11.06619,"twenty":11.803248,"median":15.475641,"eighty":18.822017,"marketCap":1894365677},{"date":"2021-11-26","current":10.935362,"twenty":11.752841,"median":15.361209,"eighty":18.799671,"marketCap":1871969996},{"date":"2021-12-03","current":10.660174,"twenty":11.700674,"median":15.25837,"eighty":18.766081,"marketCap":1824861840},{"date":"2021-12-10","current":10.64664,"twenty":11.597269,"median":15.189807,"eighty":18.713257,"marketCap":1822545046},{"date":"2021-12-17","current":10.745888,"twenty":11.515514,"median":15.166494,"eighty":18.654746,"marketCap":1839534872},{"date":"2021-12-23","current":10.957919,"twenty":11.442431,"median":15.126556,"eighty":18.639247,"marketCap":1875831320},{"date":"2021-12-31","current":10.92634,"twenty":11.368446,"median":15.085589,"eighty":18.621596,"marketCap":1870425466},{"date":"2022-01-07","current":11.738372,"twenty":11.326022,"median":15.058778,"eighty":18.579091,"marketCap":2009433139},{"date":"2022-01-14","current":11.729349,"twenty":11.326022,"median":15.040904,"eighty":18.531427,"marketCap":2007888610},{"date":"2022-01-21","current":10.863182,"twenty":11.299875,"median":15.028989,"eighty":18.489553,"marketCap":1859613758},{"date":"2022-01-28","current":11.023748,"twenty":11.261979,"median":15.001772,"eighty":18.453467,"marketCap":1851118845},{"date":"2022-02-04","current":11.088134,"twenty":11.181448,"median":14.930112,"eighty":18.423167,"marketCap":1861930553},{"date":"2022-02-11","current":10.92717,"twenty":11.115728,"median":14.912327,"eighty":18.41438,"marketCap":1834901283},{"date":"2022-02-18","current":10.92717,"twenty":11.065654,"median":14.87528,"eighty":18.386528,"marketCap":1834901283},{"date":"2022-02-25","current":10.732094,"twenty":11.023748,"median":14.820597,"eighty":18.371521,"marketCap":1802143926},{"date":"2022-03-04","current":10.629654,"twenty":11.007105,"median":14.772796,"eighty":18.349914,"marketCap":1784942161},{"date":"2022-03-11","current":10.652348,"twenty":10.957288,"median":14.734826,"eighty":18.315942,"marketCap":1788752883},{"date":"2022-03-18","current":10.806664,"twenty":10.92634,"median":14.709739,"eighty":18.308123,"marketCap":1814665792},{"date":"2022-03-25","current":10.720428,"twenty":10.866543,"median":14.669048,"eighty":18.291682,"marketCap":1800185049},{"date":"2022-04-01","current":10.629654,"twenty":10.847714,"median":14.635382,"eighty":18.253335,"marketCap":1784942161},{"date":"2022-04-08","current":10.053238,"twenty":10.819838,"median":14.583758,"eighty":18.229989,"marketCap":1688149823},{"date":"2022-04-14","current":10.071393,"twenty":10.805336,"median":14.512906,"eighty":18.210171,"marketCap":1691198401},{"date":"2022-04-22","current":10.171245,"twenty":10.764,"median":14.497563,"eighty":18.192392,"marketCap":1707965577},{"date":"2022-04-29","current":10.150722,"twenty":10.733654,"median":14.451873,"eighty":18.177577,"marketCap":1657856535},{"date":"2022-05-06","current":10.297502,"twenty":10.713769,"median":14.383195,"eighty":18.14275,"marketCap":1681829155},{"date":"2022-05-13","current":9.954658,"twenty":10.67461,"median":14.304676,"eighty":18.117189,"marketCap":1625834598},{"date":"2022-05-20","current":10.078233,"twenty":10.650249,"median":14.249341,"eighty":18.096905,"marketCap":1646017372},{"date":"2022-05-27","current":10.572534,"twenty":10.629654,"median":14.193648,"eighty":18.064002,"marketCap":1726748469},{"date":"2022-06-03","current":10.412344,"twenty":10.620376,"median":14.117725,"eighty":18.057139,"marketCap":1700585614},{"date":"2022-06-10","current":10.000427,"twenty":10.605236,"median":13.994542,"eighty":18.016495,"marketCap":1633309699},{"date":"2022-06-17","current":9.92262,"twenty":10.570637,"median":13.872371,"eighty":17.998745,"marketCap":1620602026},{"date":"2022-06-24","current":10.165194,"twenty":10.552314,"median":13.685465,"eighty":17.991294,"marketCap":1660220065},{"date":"2022-07-01","current":10.513034,"twenty":10.530137,"median":13.611721,"eighty":17.968495,"marketCap":1717030837},{"date":"2022-07-08","current":10.31623,"twenty":10.524934,"median":13.456373,"eighty":17.95339,"marketCap":1684887900},{"date":"2022-07-15","current":10.288769,"twenty":10.512341,"median":13.392091,"eighty":17.910649,"marketCap":1680402839},{"date":"2022-07-22","current":10.613725,"twenty":10.505887,"median":13.327225,"eighty":17.849237,"marketCap":1733476061},{"date":"2022-07-29","current":11.467199,"twenty":10.505887,"median":13.302306,"eighty":17.813962,"marketCap":1809111112},{"date":"2022-08-05","current":11.377758,"twenty":10.505887,"median":13.239282,"eighty":17.786291,"marketCap":1795000639},{"date":"2022-08-12","current":11.739288,"twenty":10.505887,"median":13.221695,"eighty":17.762714,"marketCap":1852037025},{"date":"2022-08-19","current":11.748717,"twenty":10.505887,"median":13.209959,"eighty":17.748875,"marketCap":1853524605},{"date":"2022-08-26","current":11.296118,"twenty":10.505887,"median":13.188531,"eighty":17.733901,"marketCap":1782120768},{"date":"2022-09-02","current":10.848234,"twenty":10.505887,"median":13.150076,"eighty":17.684237,"marketCap":1711460720},{"date":"2022-09-09","current":10.928381,"twenty":10.505887,"median":13.130958,"eighty":17.66138,"marketCap":1724105150},{"date":"2022-09-16","current":11.036817,"twenty":10.505887,"median":13.113536,"eighty":17.644475,"marketCap":1741212319},{"date":"2022-09-23","current":10.980242,"twenty":10.505887,"median":13.081395,"eighty":17.623016,"marketCap":1732286840},{"date":"2022-09-30","current":9.193418,"twenty":10.478391,"median":13.065324,"eighty":17.59628,"marketCap":1450390441},{"date":"2022-10-07","current":9.075554,"twenty":10.469523,"median":13.052449,"eighty":17.561143,"marketCap":1431795692},{"date":"2022-10-14","current":9.580013,"twenty":10.437974,"median":13.034632,"eighty":17.546569,"marketCap":1511381219},{"date":"2022-10-21","current":9.716736,"twenty":10.425892,"median":13.011756,"eighty":17.514492,"marketCap":1532951128},{"date":"2022-10-28","current":10.271339,"twenty":10.389888,"median":12.992653,"eighty":17.479985,"marketCap":1683636796},{"date":"2022-11-04","current":10.266754,"twenty":10.377223,"median":12.955005,"eighty":17.444428,"marketCap":1682885173},{"date":"2022-11-11","current":10.291061,"twenty":10.357421,"median":12.934931,"eighty":17.408903,"marketCap":1686869566},{"date":"2022-11-18","current":10.064186,"twenty":10.320716,"median":12.924436,"eighty":17.359105,"marketCap":1649681083},{"date":"2022-11-25","current":10.272911,"twenty":10.310098,"median":12.883192,"eighty":17.323674,"marketCap":1683894487},{"date":"2022-12-02","current":10.204848,"twenty":10.293993,"median":12.857307,"eighty":17.216387,"marketCap":1672737942},{"date":"2022-12-09","current":9.973436,"twenty":10.282719,"median":12.842174,"eighty":17.162345,"marketCap":1634805690},{"date":"2022-12-16","current":9.360873,"twenty":10.269156,"median":12.829982,"eighty":17.036971,"marketCap":1534396787},{"date":"2022-12-23","current":9.719335,"twenty":10.253097,"median":12.811402,"eighty":16.964208,"marketCap":1593154590},{"date":"2022-12-30","current":9.69211,"twenty":10.230259,"median":12.79325,"eighty":16.866633,"marketCap":1588691972},{"date":"2023-01-06","current":9.896298,"twenty":10.216454,"median":12.770698,"eighty":16.761899,"marketCap":1622161606},{"date":"2023-01-13","current":10.150398,"twenty":10.193425,"median":12.743914,"eighty":16.690368,"marketCap":1663812707},{"date":"2023-01-20","current":10.213923,"twenty":10.187062,"median":12.725033,"eighty":16.523587,"marketCap":1674225482},{"date":"2023-01-27","current":9.790009,"twenty":10.173843,"median":12.690346,"eighty":16.324736,"marketCap":1719595430},{"date":"2023-02-03","current":10.396723,"twenty":10.16752,"median":12.677807,"eighty":16.256402,"marketCap":1826163591},{"date":"2023-02-10","current":10.238158,"twenty":10.16752,"median":12.667312,"eighty":16.23143,"marketCap":1798311961},{"date":"2023-02-17","current":10.259586,"twenty":10.15802,"median":12.637027,"eighty":16.127135,"marketCap":1802075695},{"date":"2023-02-24","current":10.011024,"twenty":10.149032,"median":12.580612,"eighty":16.062409,"marketCap":1758416384},{"date":"2023-03-03","current":9.946656,"twenty":10.12732,"median":12.54984,"eighty":16.029311,"marketCap":1747110222},{"date":"2023-03-10","current":8.806492,"twenty":10.110262,"median":12.491259,"eighty":15.99002,"marketCap":1546842669},{"date":"2023-03-17","current":8.551231,"twenty":10.087476,"median":12.467781,"eighty":15.924154,"marketCap":1502006690},{"date":"2023-03-24","current":8.308734,"twenty":10.075497,"median":12.378703,"eighty":15.861307,"marketCap":1459412470},{"date":"2023-03-31","current":8.159832,"twenty":10.060803,"median":12.352386,"eighty":15.839714,"marketCap":1433258125},{"date":"2023-04-06","current":7.704617,"twenty":10.04356,"median":12.287536,"eighty":15.796939,"marketCap":1353300555},{"date":"2023-04-14","current":7.832247,"twenty":10.027135,"median":12.261119,"eighty":15.730693,"marketCap":1375718565},{"date":"2023-04-21","current":7.74716,"twenty":10.017452,"median":12.211348,"eighty":15.694,"marketCap":1360773225},{"date":"2023-04-28","current":7.593207,"twenty":9.999766,"median":12.160062,"eighty":15.664957,"marketCap":1307717267},{"date":"2023-05-05","current":6.573548,"twenty":9.989771,"median":12.09154,"eighty":15.642667,"marketCap":1132109520},{"date":"2023-05-12","current":6.495446,"twenty":9.971621,"median":11.987273,"eighty":15.600987,"marketCap":1118658713},{"date":"2023-05-19","current":7.029498,"twenty":9.961387,"median":11.888242,"eighty":15.530275,"marketCap":1210634281},{"date":"2023-05-26","current":7.046909,"twenty":9.952827,"median":11.808802,"eighty":15.39865,"marketCap":1213632756},{"date":"2023-06-02","current":7.116551,"twenty":9.943684,"median":11.780347,"eighty":15.324881,"marketCap":1225626656},{"date":"2023-06-09","current":7.90873,"twenty":9.929925,"median":11.738372,"eighty":15.203096,"marketCap":1362057268},{"date":"2023-06-16","current":7.934846,"twenty":9.905841,"median":11.713953,"eighty":15.174007,"marketCap":1366554981},{"date":"2023-06-23","current":7.221014,"twenty":9.886325,"median":11.649929,"eighty":15.134319,"marketCap":1243617506},{"date":"2023-06-30","current":7.260188,"twenty":9.866996,"median":11.584988,"eighty":15.109317,"marketCap":1250364075},{"date":"2023-07-07","current":6.946798,"twenty":9.848756,"median":11.548897,"eighty":15.068412,"marketCap":1196391525},{"date":"2023-07-14","current":7.499583,"twenty":9.820363,"median":11.505283,"eighty":15.049841,"marketCap":1291593106},{"date":"2023-07-21","current":8.108951,"twenty":9.78572,"median":11.467199,"eighty":15.032889,"marketCap":1396539731},{"date":"2023-07-28","current":8.682159,"twenty":9.742349,"median":11.428126,"eighty":15.003286,"marketCap":1432521431},{"date":"2023-08-04","current":8.409258,"twenty":9.731294,"median":11.387173,"eighty":14.9415,"marketCap":1387493907},{"date":"2023-08-11","current":8.120111,"twenty":9.718285,"median":11.354912,"eighty":14.916422,"marketCap":1339785831},{"date":"2023-08-18","current":7.624539,"twenty":9.704927,"median":11.300777,"eighty":14.879018,"marketCap":1258018387},{"date":"2023-08-25","current":7.506329,"twenty":9.663774,"median":11.282731,"eighty":14.826043,"marketCap":1238514226},{"date":"2023-09-01","current":7.492689,"twenty":9.624389,"median":11.244446,"eighty":14.781733,"marketCap":1236263745},{"date":"2023-09-08","current":7.310828,"twenty":9.599052,"median":11.197237,"eighty":14.751943,"marketCap":1206257344},{"date":"2023-09-15","current":7.388119,"twenty":9.572255,"median":11.168825,"eighty":14.716388,"marketCap":1219010065},{"date":"2023-09-22","current":6.997117,"twenty":9.538302,"median":11.11225,"eighty":14.678775,"marketCap":1154496301},{"date":"2023-09-29","current":6.951652,"twenty":9.501581,"median":11.06619,"eighty":14.644899,"marketCap":1146994701},{"date":"2023-10-06","current":6.951652,"twenty":9.471361,"median":11.046743,"eighty":14.595078,"marketCap":1146994701},{"date":"2023-10-13","current":6.792523,"twenty":9.431033,"median":11.012054,"eighty":14.515019,"marketCap":1120739099},{"date":"2023-10-20","current":6.542463,"twenty":9.372419,"median":10.980475,"eighty":14.499896,"marketCap":1079480297},{"date":"2023-10-27","current":7.170747,"twenty":9.358917,"median":10.957919,"eighty":14.471655,"marketCap":1076479657},{"date":"2023-11-03","current":7.537213,"twenty":9.227549,"median":10.936586,"eighty":14.399708,"marketCap":1131493992},{"date":"2023-11-10","current":7.179977,"twenty":9.151165,"median":10.92634,"eighty":14.31961,"marketCap":1077865333},{"date":"2023-11-17","current":7.734589,"twenty":9.108811,"median":10.883634,"eighty":14.267749,"marketCap":1161124242},{"date":"2023-11-24","current":7.594687,"twenty":9.078197,"median":10.857,"eighty":14.214839,"marketCap":1140121995},{"date":"2023-12-01","current":7.60468,"twenty":8.976162,"median":10.840069,"eighty":14.143037,"marketCap":1141622155},{"date":"2023-12-08","current":8.214253,"twenty":8.928966,"median":10.82028,"eighty":14.03685,"marketCap":1233131947},{"date":"2023-12-15","current":9.103631,"twenty":8.896863,"median":10.805953,"eighty":13.930523,"marketCap":1366646233},{"date":"2023-12-22","current":9.083645,"twenty":8.896863,"median":10.78687,"eighty":13.759594,"marketCap":1363645912},{"date":"2023-12-29","current":9.223547,"twenty":8.892939,"median":10.761277,"eighty":13.668342,"marketCap":1384648159},{"date":"2024-01-05","current":8.743883,"twenty":8.862382,"median":10.745888,"eighty":13.56351,"marketCap":1312640455},{"date":"2024-01-12","current":8.583995,"twenty":8.806492,"median":10.720428,"eighty":13.408162,"marketCap":1288637886},{"date":"2024-01-19","current":8.309187,"twenty":8.772881,"median":10.697142,"eighty":13.342249,"marketCap":1247383472},{"date":"2024-01-26","current":8.828824,"twenty":8.752732,"median":10.656886,"eighty":13.316627,"marketCap":1325391819},{"date":"2024-02-02","current":9.490046,"twenty":8.752732,"median":10.64215,"eighty":13.30073,"marketCap":1218502920},{"date":"2024-02-09","current":8.830529,"twenty":8.752732,"median":10.629654,"eighty":13.236743,"marketCap":1133822213},{"date":"2024-02-16","current":9.326626,"twenty":8.752732,"median":10.620577,"eighty":13.221244,"marketCap":1197520090},{"date":"2024-02-23","current":8.865547,"twenty":8.752732,"median":10.61055,"eighty":13.209959,"marketCap":1138318534},{"date":"2024-03-01","current":8.801346,"twenty":8.74965,"median":10.589265,"eighty":13.19135,"marketCap":1130075279},{"date":"2024-03-08","current":8.986315,"twenty":8.743883,"median":10.567288,"eighty":13.154274,"marketCap":1153824926},{"date":"2024-03-15","current":8.329352,"twenty":8.723902,"median":10.538449,"eighty":13.128485,"marketCap":1069472190},{"date":"2024-03-22","current":8.96157,"twenty":8.698898,"median":10.5269,"eighty":13.112465,"marketCap":1150647615},{"date":"2024-03-28","current":8.466976,"twenty":8.693607,"median":10.517516,"eighty":13.098537,"marketCap":1087142753},{"date":"2024-04-05","current":8.466976,"twenty":8.653336,"median":10.488954,"eighty":13.065324,"marketCap":1087142753},{"date":"2024-04-12","current":7.990046,"twenty":8.61897,"median":10.476162,"eighty":13.052449,"marketCap":1025905922},{"date":"2024-04-19","current":8.671317,"twenty":8.578848,"median":10.466677,"eighty":13.034632,"marketCap":1040072426},{"date":"2024-04-26","current":9.585747,"twenty":8.579877,"median":10.437517,"eighty":13.020302,"marketCap":1149752791},{"date":"2024-05-03","current":9.605463,"twenty":8.579877,"median":10.431596,"eighty":12.999364,"marketCap":1152117669},{"date":"2024-05-10","current":10.091416,"twenty":8.579877,"median":10.40199,"eighty":12.962642,"marketCap":1210404831},{"date":"2024-05-17","current":10.167149,"twenty":8.579877,"median":10.387579,"eighty":12.944965,"marketCap":1219488545},{"date":"2024-05-24","current":9.554974,"twenty":8.579877,"median":10.368229,"eighty":12.926046,"marketCap":1146061860},{"date":"2024-05-31","current":9.031155,"twenty":8.579877,"median":10.357421,"eighty":12.90972,"marketCap":1083232842},{"date":"2024-06-07","current":8.639868,"twenty":8.579877,"median":10.32448,"eighty":12.882781,"marketCap":1036300321},{"date":"2024-06-14","current":8.494713,"twenty":8.57296,"median":10.31623,"eighty":12.877209,"marketCap":1018889870},{"date":"2024-06-21","current":8.53258,"twenty":8.56142,"median":10.296725,"eighty":12.877995,"marketCap":1023431727},{"date":"2024-06-28","current":8.608313,"twenty":8.557426,"median":10.288769,"eighty":12.87427,"marketCap":1032515441},{"date":"2024-07-05","current":9.17631,"twenty":8.557426,"median":10.28051,"eighty":12.856219,"marketCap":1100643293},{"date":"2024-07-12","current":10.066172,"twenty":8.557426,"median":10.267199,"eighty":12.83418,"marketCap":1207376927},{"date":"2024-07-15","current":10.141905,"twenty":8.557426,"median":10.266754,"eighty":12.829982,"marketCap":1216460640},{"date":"2024-08-02","current":30.236968,"twenty":8.550513,"median":10.244363,"eighty":12.813454,"marketCap":2311767376},{"date":"2024-08-09","current":28.994819,"twenty":8.550513,"median":10.244363,"eighty":12.829982,"marketCap":2216798880},{"date":"2024-08-16","current":30.839915,"twenty":8.550513,"median":10.244363,"eighty":12.847792,"marketCap":2357865738},{"date":"2024-08-23","current":30.942317,"twenty":8.550513,"median":10.244363,"eighty":12.868391,"marketCap":2365694844},{"date":"2024-08-30","current":32.290603,"twenty":8.550513,"median":10.244363,"eighty":12.926535,"marketCap":2468778073},{"date":"2024-09-06","current":31.86393,"twenty":8.550513,"median":10.244363,"eighty":12.95098,"marketCap":2436156798},{"date":"2024-09-13","current":30.379109,"twenty":8.550513,"median":10.244363,"eighty":12.978743,"marketCap":2322634762},{"date":"2024-09-20","current":33.178083,"twenty":8.550513,"median":10.244363,"eighty":12.986356,"marketCap":2536630324},{"date":"2024-09-27","current":30.92525,"twenty":8.550513,"median":10.244363,"eighty":13.030742,"marketCap":2364389993},{"date":"2024-10-04","current":30.174306,"twenty":8.550513,"median":10.244363,"eighty":13.065239,"marketCap":2306976550},{"date":"2024-10-11","current":30.874049,"twenty":8.550513,"median":10.244363,"eighty":13.110396,"marketCap":2360475440},{"date":"2024-10-18","current":33.980228,"twenty":8.550513,"median":10.244363,"eighty":13.135891,"marketCap":2597958321},{"date":"2024-10-25","current":32.512473,"twenty":8.550513,"median":10.244363,"eighty":13.18261,"marketCap":2485741135},{"date":"2024-10-31","current":26.328623,"twenty":8.550513,"median":10.244363,"eighty":13.18261,"marketCap":2483131433},{"date":"2024-11-08","current":29.275547,"twenty":8.550153,"median":10.241149,"eighty":13.17502,"marketCap":2761064694},{"date":"2024-11-15","current":29.635999,"twenty":8.550153,"median":10.241149,"eighty":13.220364,"marketCap":2795059964},{"date":"2024-11-22","current":28.847366,"twenty":8.550153,"median":10.241149,"eighty":13.27236,"marketCap":2720681617},{"date":"2024-11-29","current":29.220929,"twenty":8.550153,"median":10.241149,"eighty":13.402862,"marketCap":2755913466},{"date":"2024-12-06","current":28.529146,"twenty":8.550153,"median":10.241149,"eighty":13.662197,"marketCap":2690669302},{"date":"2024-12-13","current":28.10024,"twenty":8.550153,"median":10.241149,"eighty":13.941658,"marketCap":2650217921},{"date":"2024-12-20","current":25.789683,"twenty":8.550153,"median":10.241149,"eighty":14.183552,"marketCap":2432302415},{"date":"2024-12-27","current":26.509138,"twenty":8.550153,"median":10.241149,"eighty":14.332934,"marketCap":2500156345},{"date":"2025-01-03","current":25.734341,"twenty":8.550153,"median":10.241149,"eighty":14.482787,"marketCap":2427082882},{"date":"2025-01-10","current":25.720505,"twenty":8.549794,"median":10.239653,"eighty":14.532851,"marketCap":2425777998},{"date":"2025-01-17","current":26.619823,"twenty":8.549794,"median":10.239653,"eighty":14.674786,"marketCap":2510595411},{"date":"2025-01-24","current":26.24626,"twenty":8.549794,"median":10.239653,"eighty":14.756709,"marketCap":2475363563},{"date":"2025-01-31","current":20.963976,"twenty":8.549794,"median":10.239653,"eighty":14.865144,"marketCap":2421863349},{"date":"2025-02-07","current":22.127386,"twenty":8.549794,"median":10.239653,"eighty":14.930454,"marketCap":2556266325},{"date":"2025-02-14","current":21.3819,"twenty":8.549794,"median":10.239653,"eighty":15.030776,"marketCap":2470144030},{"date":"2025-02-21","current":20.6703,"twenty":8.549794,"median":10.239653,"eighty":15.049841,"marketCap":2387936384},{"date":"2025-02-28","current":20.24108,"twenty":8.549794,"median":10.239653,"eighty":15.119808,"marketCap":2338350819},{"date":"2025-03-07","current":19.574836,"twenty":8.549435,"median":10.238158,"eighty":15.219892,"marketCap":2261382913},{"date":"2025-03-14","current":18.818048,"twenty":8.556094,"median":10.256731,"eighty":15.427951,"marketCap":2173954953},{"date":"2025-03-21","current":19.168203,"twenty":8.563982,"median":10.270461,"eighty":15.642559,"marketCap":2214406696},{"date":"2025-03-28","current":19.642608,"twenty":8.589386,"median":10.284192,"eighty":15.976834,"marketCap":2269212283},{"date":"2025-04-04","current":18.08385,"twenty":8.61897,"median":10.295948,"eighty":16.156501,"marketCap":2089136782},{"date":"2025-04-11","current":16.76376,"twenty":8.629342,"median":10.308893,"eighty":16.250162,"marketCap":1936633430},{"date":"2025-04-17","current":17.215614,"twenty":8.672243,"median":10.320508,"eighty":16.320056,"marketCap":1988833792},{"date":"2025-04-25","current":14.956124,"twenty":8.693028,"median":10.339114,"eighty":16.512412,"marketCap":2205594545},{"date":"2025-04-29","current":14.646015,"twenty":8.698894,"median":10.357421,"eighty":16.512412,"marketCap":2159862431}],"updateTime":1746030348826}}}